The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - Within the history of the biotechnology sector, few franchises have gone from blockbuster status to peak to decline as quickly as that of Incivek, Vertex … Continue Reading
Read nowLong Ideas - Keryx Biopharmaceuticals’ (KERX) CEO, Ron Bentsur, spent much of the company’s 4Q/YE12 earnings conference call reviewing patents, pending patents, and potential exclusivity designations for Zerenex, … Continue Reading
Read nowLong Ideas - Amedisys, Inc. (AMED) reported 4Q and year-end earnings Tuesday morning, and the key highlight was the company’s 2013 EPS guidance range of $0.60-$0.70, substantially below … Continue Reading
Read nowLong Ideas - With U.S. rights to Horizant returning in full to XenoPort (XNPT) in just two months, and a number of significant developmental catalysts within the same … Continue Reading
Read nowLong Ideas - Wet macular degeneration is a chronic eye disease that causes vision loss and generally occurs later in life (50+), as blood vessels leak fluid or … Continue Reading
Read nowLong Ideas - We kicked off the week with a quick technical blurb about Sarepta Therapeutics, although we didn’t get into the details of our bullish long-term outlook. … Continue Reading
Read nowLong Ideas - Recalls in the biotechnology sector don’t occur frequently, but when they do, they present severe challenges to the drug manufacturer. For investors, these events also … Continue Reading
Read now
